{"id":3038,"date":"2017-05-22T15:52:15","date_gmt":"2017-05-22T14:52:15","guid":{"rendered":"https:\/\/lscconnect.com\/consultantconnect\/munster-perfectly-placed-for-the-biotech-boom\/"},"modified":"2020-12-15T17:45:34","modified_gmt":"2020-12-15T17:45:34","slug":"munster-perfectly-placed-for-the-biotech-boom","status":"publish","type":"post","link":"https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/05\/22\/munster-perfectly-placed-for-the-biotech-boom\/","title":{"rendered":"Munster \u2013 perfectly placed for the Biotech Boom!"},"content":{"rendered":"

Ireland now a\u00a0top global Biotech manufacturing hub<\/h2>\n

Biotech drugs (vaccines, biologics) continue to gain traction in the Life Sciences sector<\/a>. Annual sales of Biopharmaceuticals are now estimated at over $280 billion globally, and an increasing number and percentage of Pharmaceuticals entering the market are Biopharmaceuticals. Ireland has successfully grown its presence in this market niche and is now recognized as one of the top global Biotech manufacturing<\/strong> hubs.<\/p>\n

Munster has always been a key location for Biotech companies since the first Irish Biotech investment by Schering Plough Brinny (now MSD) in 1983. This trailblazing investment was followed by other major Pharma companies<\/a> making significant strategic investments in Biotech in Cork such as Eli Lilly, Janssen and Pfizer (this facility is now owned by BioMarin).<\/p>\n

These investments haven\u2019t been a one off either with continuous investment on the sites to support additional capacity, capabilities and technologies such as MSD\u2019s 2011 investment in the Brinny Pneumococcal Vaccine Conjugation Facility and Eli Lilly\u2019s 2017 announcement which signalled a new Biotech build program to significantly increase capacity at their Kinsale campus.<\/p>\n

Biotech growth throughout Munster<\/h3>\n

The growth of the Biotech sector in Munster hasn\u2019t been limited to Cork and has spread to other counties for example Regeneron Limerick, Amneal Tipperary and Sanofi Waterford.<\/p>\n

As well as the growing number of facilities, Munster is home to a diverse range of facilities supporting different markets for example Janssen Ringaskiddy is focussed on low\/mid-volume-rapid-prototyping for clinical trial and early stage commercialisation. BioMarin and Regeneron are focussed on some of the most acute and debilitating orphan\/rare diseases. While MSD Brinny, Eli Lilly Kinsale and Sanofi Waterford produce market leading high volume global drug products that support millions of patients worldwide.<\/p>\n

The investment in Munster Biopharma remains consistent, with announcements in 2015 by Amneal in Tipperary focusing on high-end speciality medications and Biosimilars and the exciting GE BioPark announcement in 2016 with an innovative hub and spoke, multi-tenant, rapid deployment campus.<\/p>\n

All of this commercial Biotech activity is made possible because of the support infrastructure in place in Munster including:<\/p>\n